JAGUAR HEALTH, INC. Revenue from Contract with Customer, Excluding Assessed Tax
JAGUAR HEALTH, INC. (JAGX) reported Revenue from Contract with Customer, Excluding Assessed Tax of $883.85 thousand for the 3-month period ending 2018-06-30, per its 10-Q filed 2018-08-13.
Discontinued › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2018-08-13
- JAGUAR HEALTH, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2018-06-30 was $883.85K, a 1.41% decline year-over-year.
- JAGUAR HEALTH, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2017-06-30 was $896.52K.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month |
|---|---|---|
| 2018-06-30 | $883.85K 10-Q · filed 2018-08-13 | $1.69M 10-Q · filed 2018-08-13 |
| 2017-06-30 | $896.52K 10-Q · filed 2018-08-13 | $1.72M 10-Q · filed 2018-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |